industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘DNA sequencing’


Monday, February 15th, 2010

Howard Leight / Sperian Hearing Protection Experts to Present at National Hearing Conservation Association Conference

SMITHFIELD, RHODE ISLAND, U.S.A. — February 15, 2010— Hearing conservation experts from Howard Leight / Sperian Hearing Protection will be presenters at the 2010 National Hearing Conservation Association’s (NHCA) Conference, February 25-27, 2010, in Orlando, Fla.

Brad K. Witt, Director of Hearing Conservation, and Dr. Theresa Y. Schulz, Lt. Col., USAF (ret), CPS/A, Hearing Conservation Manager, both of Howard Leight/Sperian Hearing Protection, LLC will participate in two key workshops at the NHCA’s “Explore the World of Hearing Loss Prevention” Conference.

“Howard Leight has always been dedicated to the prevention of occupational hearing loss,” Renee Bessette, COHC, Marketing Manager, Howard Leight/Sperian Hearing Protection, LLC said. “We are a proud member of NHCA and are pleased to share our knowledge, experience and best practices in hearing loss prevention with this audience.”

The workshops are:

  • “Hands-on fit-testing,” Thursday, Feb. 25. As part of the full-day workshop focusing on the world’s leading fit-testing technologies available to the hearing conservation professional, Witt will present details of Howard Leight’s new VeriPRO® technology that enables safety managers to ensure their employees are getting the most out of their hearing protection devices. The VeriPRO system measures real-world attenuation of unmodified earplugs and can be used as a means to improve individual employee training and enhance the overall effectiveness of hearing conservation programs. Hands-on demonstrations of all available technologies will follow in the afternoon.

  • “Hearing loss prevention: The basics/Hearing Protective Devices”, Thursday, Feb. 25. Presented by Dr. Schulz, this section of “The Basics” workshop will focus on hearing protector function, how hearing protection devices (HPDs) are tested and rated (with particular reference to the Noise Reduction Rating), and the performance gains available from the use of dual hearing protection.

“Hearing conservationists can measure, assess, document, and counsel, but when it comes to effective intervention, our primary and sometimes only tool, is a hearing protector. We all must become more knowledgeable about the specification of hearing protection devices and their use in our hearing conservation programs,” Dr. Schulz said.

For more information about the NHCA’s “Explore the World of Hearing Loss Prevention” Conference in February, visit http://www.hearingconservation.org.

About Howard Leight / Sperian Hearing Protection

Howard Leight/Sperian Hearing Protection, LLC is a leading global provider of passive and intelligent hearing protection solutions, and the founder of the HearForever™ initiative. For over 30 years, Howard Leight has pursued the prevention of occupational hearing loss through innovation in hearing protection design, technology, performance and comfort, and the promotion of progressive Hearing Conservation Programs. Leading solutions include the highest attenuating Max® single-use earplug; patented Air Flow Control™ technology for optimal earmuff attenuation; QuietDose™ personal in-ear dosimetry; and the industry-changing VeriPRO® earplug fit testing system. Visit: http://www.howardleight.com.

Visit the HearForever Web site at http://www.hearforever.org. Follow HearForever on Twitter (@HearForeverOrg) at http://twitter.com/HearForeverOrg and find us on Facebook at http://facebook.com/HearForever.

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Bookmark and Share

Tags: , , , , , , , , , , , , ,
Posted in Hearing Protection, Manufacturing, Public Safety |


Tuesday, May 26th, 2009

RainDance Technologies Announces First European Order for Sequence Enrichment Solution to ATLAS Biolabs

rdt-702290VIENNA, AUSTRIA, May 26, 2009 – RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced it has received the first European order for its Sequence Enrichment Solution from ATLAS Biolabs GmbH of Berlin, Germany, a leading genomic services provider.

In an announcement at the European Society of Human Genetics (ESHG) Conference 2009, the company said ATLAS Biolabs’ purchase includes the RDT 1000 system, PCR primer libraries, consumables kits, and training services.

“ATLAS Biolabs is a renowned genomic services provider with an esteemed scientific team that is highly respected in the European research community,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “We look forward to supporting their requirements with a solution that can dramatically enhance their genomic research services portfolio.”

McNary said the sale represents a key addition to the company’s global service provider network. “With our Sequence Enrichment Solution in place at ATLAS Biolabs, European researchers will have immediate access to our technology. It will enable scientists to perform high-resolution analysis of genetic variation between individuals within populations at a level unmatched by current methodologies,” he said.

“Our customers now are exploring the contribution of rare variants in their study of disease and are adopting targeted genomic sequencing methods to study large populations in this context. RainDance’s massively parallel microdroplet PCR-based solution for sequence enrichment is superior to all others available in the market because it is less prone to the selection bias associated with targeted sequencing,” said Dr. Peter Nürnberg, Co-Founder and Chief Executive Officer, ATLAS Biolabs. “Using the RainDance technology, we can amplify up to 4000 amplicons in a single PCR process with essentially no allelic amplification bias and a near 100% success rate of PCR primer pairs.”

Nürnberg said ATLAS Biolabs is discussing the RainDance Sequence Enrichment Solution with key customers and will invite them to perform proof-of-principle experiments once the instrument is installed. “We are pleased to be the first in Europe to offer this innovative approach and will work with RainDance to explore additional applications for their promising new technology.”

RainDance will immediately begin designing custom DNA primer libraries for ATLAS Biolabs’ customers and anticipates shipping the RDT 1000 system by July 2009.

“The first sale of our Sequence Enrichment Solution in Europe is a major step in our company’s growth,” said McNary. “Our technology is generating considerable interest in the region, and we anticipate announcing additional sales to leading European genomic and medical research centers in the coming weeks.”

For sales information, contact Patrick Kelly, Director of Sales – European Region, RainDance Technologies, at kellyp@raindancetech.com or +44-786-3200-242.

About RainDance Technologies, Inc.

RainDance Technologies, Inc., based in Lexington, Massachusetts, U.S.A., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application focuses on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

About ATLAS Biolabs

ATLAS Biolabs GmbH is a leading provider of microarray-based genomic services such as genome-wide gene expression and SNP analyses, CGH analyses, and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological, and diagnostic enterprises. The company is based in Berlin and Cologne, Germany.

Bookmark and Share

Tags: , , , , , ,
Posted in Biosciences |


Tuesday, May 5th, 2009

RainDance Technologies CEO to Present at Transformational Tools Panel During 2009 BIO International Convention

LEXINGTON, MASSACHUSETTS, U.S.A., May 5, 2009 — Christopher McNary, RainDance Technologies President and Chief Executive Officer, will discuss the impact of new transformational tools shaping life sciences research during a panel session at the 2009 BIO International Convention in Atlanta on May 20, 2009.

The session, Transformational Tools: How New Research Technologies Are Changing the Rules of the Game, will review how the accessibility and power of these new tools are empowering individual scientists to conduct research that was formerly infeasible, unaffordable, or threatening to the research status quo.

In his remarks, McNary will discuss how exciting new technologies are enabling researchers to rethink the way they design experiments and approach discovery, permitting the achievement of previously unattainable breakthrough science. He will cite that the capabilities of his company’s RainStormTM microdroplet-based technology platform can be applied across a wide range of biomedical research applications. For example, McNary will describe how a researcher can collect a heterogeneous group of cells of interest, such as a cancer sample, break it down into homogeneous collections of primary cells such as tumor and stem cells, capture and interrogate these as single cells, and perform scientific analyses. This capability will help make exciting strides in understanding the fundamental biology of complex disease.

In addition, McNary will explain how the RainStorm platform also is being applied in collaboration with sanofi-aventis to develop game-changing high-throughput screening methodologies for drug discovery. This work will accelerate the discovery process by enabling pharmaceutical companies to make better and faster decisions about what compounds should be pulled through their development pipelines. McNary will review how these new workflows minimize experimental unknowns, permit simple sample manipulation, and generate accurate measurements at levels unimaginable only a few years ago.

McNary and the other chief executives on the panel also will describe the radical innovations, new perspectives, and diverse disciplines underlying these new technologies, as well as challenges to development and commercialization.

To learn more, visit the RainDance Technologies Website at www.raindancetech.com, or call 781-861-6300.

For more information about the 2009 BIO International Convention, visit http://convention.bio.org/.

About RainDance Technologies, Inc.
RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/
bookmark to del.icio.us

Technorati tags: , , , , , ,

Bookmark and Share

Tags: , , , , , ,
Posted in Biosciences |


Friday, April 17th, 2009

RainDance Technologies Announces Sale of RDT 1000, Sequence Enrichment Solution to Expression Analysis

LEXINGTON, MASSACHUSETTS, U.S.A., April 17, 2009 – RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the commercial sale of an RDT 1000 and Sequence Enrichment Solution to Expression Analysis, Inc., a leading provider of genomic services for clinical trials and research.

The RainDance solution will enable Expression Analysis to expand its service offerings to provide genomic researchers quality and efficient targeted sequencing on large sample numbers.

“As the market leader in genomic outsourcing for gene expression, genotyping, and resequencing analysis, we enable our service offerings using best-in-class systems. RainDance Technologies is clearly in this class, and we are proud to incorporate their technology to further expand our suite of services and look forward to offering expanded DNA sequencing applications,” said Steve McPhail, President and Chief Executive Officer of Expression Analysis.

The announcement marks the first sale of the RainDance solution to a service provider. The solution consists of an RDT 1000, consumables kits, custom PCR primer libraries, and expert training.

“As a leading genomic service provider, Expression Analysis’ decision to embrace our platform accelerates the ability of researchers to access our sequence enrichment technology,” said Christopher McNary, President and Chief Executive Officer of RainDance Technologies.

The RDT 1000 and Sequence Enrichment Solution utilize RainDance’s breakthrough RainStorm™ microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter-volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets, enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

The commercial version of the Sequence Enrichment Solution is now being shipped in North America and will soon be available for shipment to Europe. For more information, contact info@raindancetech.com, call 781-861-6300, or visit the company’s website at http://www.raindancetech.com/.

About RainDance Technologies, Inc.
RainDance Technologies, Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit http://www.raindancetech.com/.

RainStorm™ is a trademark of RainDance Technologies, Inc.

About Expression Analysis, Inc.
Expertise Beyond Expression — Providing whole genome to focused set gene expression and genotyping assays, along with sequencing services using RainDance Technologies, Illumina, Affymetrix, and Applied Biosystems. A leading provider of genomic services in clinical trials and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissue specimens as well as nucleic acid isolation and bioinformatic services. The company’s quality system follows CLSI guidelines and their CLIA-registered lab supports GLP compliance.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/
bookmark to del.icio.us

Technorati tags: , , , , , ,

Bookmark and Share

Tags: , , , , , ,
Posted in Biosciences |


Tuesday, March 31st, 2009

RainDance Technologies to Present Session on Sequence Enrichment Using Innovative Microdroplet-Based Solutions at “Genomics in Business” Conference

MANCHESTER, UK – 31 March, 2009 – RainDance Technologies, Inc. will present a session on sequence enrichment using innovative microdroplet-based solutions at the “Genomics in Business” conference in Amsterdam on 20 April, 2009.

Recent advances in DNA sequencing technologies have improved accuracy and dramatically reduced cost. However, even with the improved efficiency of “second-generation” systems, sequencing thousands of human genomes across various phenotypes is still economically unrealistic. To exploit the full potential of new sequencing techniques, a robust method for isolating biologically relevant genomic loci on the megabase scale will be required.

Analogous to what the massively parallel sequencing technologies have done to improve the efficiency of DNA sequencing, RainDance Technologies has developed a platform to enable the use of PCR for high-throughput amplification of targeted genomic sequences.

In the “Genomics in Business” conference session titled “New High-Throughput Sequencing and Screening Technologies,” Patrick Kelly, Director, European Sales, RainDance Technologies, will explain the application of the company’s new Sequence Enrichment technology.

“The Sequence Enrichment Solution leverages our RainStorm™ technology to manipulate picoliter-volume droplets in disposable chips. We will present the use of this novel method for enrichment of genomic loci with minimal selection bias prior to sequencing, demonstrating the utility of this approach for the routine application of targeted sequencing,” Kelly said.

To learn more about RainDance Technologies, and its revolutionary new RainStorm microdroplet-based technology, attend the session titled “New High-Throughput Sequencing and Screening Technologies” at the “Genomics in Business” conference in Amsterdam on Monday, 20 April, 2009. Or visit the RainDance Technologies website at www.raindancetech.com, or call +44-786-3200-242.

For more information about the “Genomics in Business” conference, visit www.genomicsinbusiness2009.com.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit www.raindancetech.com.

RainStorm™ is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , ,

Bookmark and Share

Tags: , , , , , ,
Posted in Biosciences |


Thursday, March 26th, 2009

RainDance Technologies Announces First Commercial Shipment of RDT 1000, Sequence Enrichment Solution

– Delivery to Ontario Institute for Cancer Research –

LEXINGTON, MASSACHUSETTS, U.S.A., March 26, 2009 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the first commercial shipment of its RDT 1000 and Sequence Enrichment Solution. The shipment will be delivered to the Ontario Institute for Cancer Research in Canada (OICR), a new, innovative institute dedicated to research in the prevention, early detection, diagnosis and treatment of cancer.

OICR will use the RainDance solution – consisting of a RDT 1000, consumables kits, custom PCR primer libraries, and expert training – in its programs involving the discovery and validation of DNA sequence variants associated with cancers. The solution is designed to increase quality and efficiency of performing targeted sequencing on large sample numbers.

“We are looking forward to implementing the RainDance platform at OICR – and to the benefits that the RainDance solution will bring to our programs,” said John McPherson, Director of OICR’s Cancer Genomics Program. “We expect the RainDance solution to become a critical element in accelerating the research phase of our studies that will ultimately result in our understanding of cancer.”

“The shipment to OICR represents a major milestone that exemplifies the power of the RainStorm™ microdroplet-based platform to those driving innovation in human health and disease research,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies. “First, leading genome centers participating in the company’s Early Access Partner program have experienced the value of the RainDance solution. Now, our commercial platform is shipping and gaining acceptance in the rapidly growing sequence enrichment segment of the next-generation sequencing market.”

The RDT 1000 and Sequence Enrichment Solution utilize RainDance’s breakthrough RainStorm™ microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

“All of us at RainDance are grateful for the opportunity to support OICR — one of the world’s leading centers of cancer research — in its mission to advance human health,” McNary said.

The commercial version of the Sequence Enrichment Solution is now being shipped in North America and will soon be available for shipment to Europe. For more information, contact info@raindancetech.com, call 781-861-6300, or visit the company’s website at http://www.raindancetech.com/.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

RainStorm™ is a trademark of RainDance Technologies, Inc.

# # #


 Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/
bookmark to del.icio.us

Technorati tags: , , , , ,

Bookmark and Share

Tags: , , , , ,
Posted in Biosciences |


Tuesday, March 17th, 2009

RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference

BOSTON, MASSACHUSETTS, U.S.A., March 17, 2009 — RainDance Technologies, Inc., a privately held provider of innovative microdroplet-based solutions for human health and disease research, today announced it will be shipping its first commercial Sequence Enrichment Solution this month and reviewed the company’s opportunities for growth at Cowen and Company’s 29th Annual Health Care Conference.

The initial application of the company’s RainStorm(TM) microdroplet-based technology platform focuses on targeted sequencing of the human genome, one of the fastest-growing segments of the rapidly expanding $1 billion DNA sequencing market. The company’s Sequence Enrichment Solution and RDT 1000 system will enable the high-resolution analysis of genetic variation between individuals within populations at a level unmatched by current methodologies.

“We will make the first commercial shipment of our Sequence Enrichment Solution in March and presently have a backlog of orders,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “Over the next 3 years, we estimate the genomic sequence enrichment market at about $400 million, and we believe RainDance can capture a significant share.”

During the last 6 months, RainDance has provided its solution to early access partners representing some of the world’s leading genome research centers. These include the J. Craig Venter Institute, The Genome Center at the Washington University School of Medicine, and the Broad Institute. The company also collaborated with the Scripps Translational Science Institute to accelerate targeted genomic sequencing in its Wellderly Study of America’s healthy elderly.

In targeted DNA sequencing applications, the Sequence Enrichment Solution provides researchers with higher resolution and statistical power while maximizing workflow efficiency and cost. “Our solution enables one next-generation sequencer to do what alternative technologies would require seven sequencers to complete in the same time,” said McNary.

The company also reviewed the application of its RainStorm technology across a wide variety of growing life sciences and applied sciences markets.

“We have announced a consortium with sanofi aventis and Université Louis Pasteur to develop the next generation of high-throughput screening and small molecule compound storage for drug discovery — a $4 billion market,” said McNary.

RainDance recently shared in a Massachusetts Life Sciences Center grant of $250,000 per year for 3 years to Dr. David Weitz, Mallinckrodt Professor of Physics and Applied Physics at Harvard’s School of Engineering and Applied Sciences and Physics Department. The grant will fund research to develop a new form of fluorescence-activated cell sorter used to collect biochemical information about individual cells.

“We also have demonstrated proof of principle of our droplet-based technology in enzymatic detection of cell surface markers, sorting based on secreted proteins from cells, immunoassays, qPCR, and enzyme-directed evolution for industrial and biofuel applications,” he said. “These studies highlight the potential of our RainStorm technology to become a true platform capable of sustaining growth for years to come.”

About RainDance Technologies, Inc.
RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

# # #

RainStorm(TM) is a trademark of RainDance Technologies, Inc.
Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , ,

Bookmark and Share

Tags: , , , ,
Posted in Biosciences |


Monday, February 16th, 2009

RainDance Technologies Appoints Patrick Kelly As European Sales Director

LEXINGTON, MASSACHUSETTS, U.S.A., February 16, 2009 – RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, has appointed Patrick Kelly to the newly created position of European Sales Director, effective immediately.

“Mr. Kelly’s appointment represents an important step in the geographic expansion of our commercial efforts with the first quarter release of our Sequence Enrichment Solution for the targeted sequencing of the human genome,” said Stephen E. Becker, Vice President, Commercial Operations, RainDance Technologies. “His international business experience in life sciences and genetics and sequencing makes him the ideal candidate to lead RainDance’s entry into the European market.”

Based in Manchester, England, Mr. Kelly will be responsible for introducing RainDance’s RainStormTM technology platform to Europe. He will work with thought leaders in genomics research to adopt RainDance’s Sequence Enrichment Solution and the RDT 1000 instrument. In addition, Mr. Kelly will build the commercial sales infrastructure required to launch the company’s solutions in the European market.

Mr. Kelly joins RainDance from Helicos Biosciences where he served as Global Business Manager for the company’s European operations. In this role, he led the positioning of the company’s next-generation sequencing technology with opinion leaders in the region. Mr. Kelly previously was Business Team Manager, Europe, Middle East, Africa, for Agilent Technologies. He also was European Site Manager and Vice President, Sales and Support, for Affymetrix Europe, where he led commercial activities for microarray systems and reagents in the research, pharmaceutical, and molecular diagnostics markets, and served as European Sales Manager for genetic analysis systems at Applied Biosystems. Mr. Kelly received a Bachelor of Science degree in Chemistry from Sheffield University and is a member of the Institute of Directors (UK).

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStormtm technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

# # #

RainStorm(TM) is a trademark of RainDance Technologies, Inc.
Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , ,

Bookmark and Share

Tags: , , ,
Posted in Biosciences |


Wednesday, February 4th, 2009

RainDance Technologies Announces Commercial Release of its Sequence Enrichment Solution

LEXINGTON, MASSACHUSETTS, U.S.A., February 4, 2009 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the commercial release of its Sequence Enrichment Solution for sales in North America.

In an announcement at the 2009 Advances in Genome Biology and Technology Conference (AGBT), the company said it has begun accepting orders for the solution and has started commercial production of the solution’s components for shipment during the first quarter.

“This milestone represents the first commercialized application of our exciting RainStorm(TM) microdroplet-based technology platform,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies. “It underscores the power of droplet-based biology to increase the depth of understanding about biological problems and increase the pace of biomedical discovery.”

The RainDance Sequence Enrichment Solution incorporates RainStorm technology for targeted sequencing applications of the human genome. It will enable the high-resolution analysis of genetic variation between individuals within populations at a level unmatched by current methodologies. The solution dramatically improves sample uniformity and reduces the selection bias typically associated with targeted sequencing.

The Sequence Enrichment Solution consists of the following components:
The RDT 1000 system generates picoliter-volume discrete PCR reactions in droplets at the unprecedented rate of 10 million per hour. It amplifies hundreds to thousands of genomic loci with high specificity and uniformity.
Custom-Order Content for DNA Primer Libraries will be available that enable the amplification of hundreds to thousands of genomic loci in a single tube. RainDance customers can design and order these libraries specifically for their research applications.
Sequence enrichment consumables kits, provide a complete workflow solution for easy implementation in the laboratory.

The company also announced that comprehensive training and support services are available to maximize the operating performance of the solution.

“This commercialization step is the culmination of a rigorous Early Access Partner program that involved some of the world’s leading genomic research institutions,” said McNary. “These organizations see the potential of our Sequence Enrichment Solution to enhance the performance of their next-generation sequencing platforms and accelerate their discovery process.”

RainDance also is presenting a workshop, “Enrichment of Genomic Loci for Targeted Sequencing Applications,” at the AGBT Conference on February 6 to explain the application and benefits of its new technology in genomics research.

For sales information, contact info@raindancetech.com or call 781-861-6300. The company said the Sequence Enrichment Solution will be available for purchase in Europe later this year.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStormtm technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

RainStorm(TM) is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , ,

Bookmark and Share

Tags: , , , , ,
Posted in Biosciences |


Friday, January 30th, 2009

“Enrichment of Genomic Loci for Targeted Sequencing Application” Is Focus of 2009 AGBT Conference Workshop

LEXINGTON, Massachusetts, USA –January 30, 2009 – Jeff Olson, Manager of Nucleic Acid Applications, of RainDance Technologies, Inc., will present “Enrichment of Genomic Loci for Targeted Sequencing Applications,” to explain application of the RainStorm micro-droplet technology on the new RDT 1000 instrument, at the 2009 Advances in Genome Biology and Technology (AGBT) conference on Friday, February 6th, in Marco Island, Florida.

RainDance Technologies is a provider of innovative microdroplet-based solutions which enable and benefit biological applications utilized in human health and disease research.

“Recent advances in DNA sequencing technologies have improved accuracy and dramatically reduced cost. However, even with the improved efficiency of “second generation” systems, sequencing thousands of human genomes across various phenotypes is still economically unrealistic. To exploit the full potential of new sequencing techniques, a robust method for isolating biologically relevant genomic loci on the megabase scale will be required,” said Olson.

Olson has more than twenty years of experience in molecular biology, technology development and DNA diagnostics. He manages the Nucleic Acids Applications group at RainDance Technologies (http://www.raindancetech.com/) and is responsible for the development of the company’s Sequence Enrichment application.

Olson will present “Enrichment of Genomic Loci for Targeted Sequencing Applications” at the 2009 AGBT meeting on Friday, February 6th, at 2:00 p.m. in the Islands Ballroom at the Marco Island Marriott Resort, Golf Club & Spa, Florida.

The 2009 Advances in Genome Biology and Technology conference (http://www.agbt.org/), a premier scientific forum for capturing the latest advances in new DNA sequencing technologies and for presentations on the applications of genomics to diverse areas in biology and biomedicine, runs February 4-7, 2009.

About RainDance Technologies
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimize process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

RainStorm™ is a trademark of RainDance Technologies, Inc.

# # #


Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , ,

Bookmark and Share

Tags: , , , , ,
Posted in Biosciences |

« Older Entries

Industry PR is proudly powered by WordPress.
WordPress